FDA Approves SYNJARDY XR — Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim today announced the FDA approval of SYNJARDY XR Empagliflozin/Metformin Hydrochloride, an extended-release oral tablet designed to improve glycemic control in Type 2 diabetes. This move is expected to expand the company’s market share in the second-line oral antidiabetic landscape, offering a differentiated combination therapy to compete against other fixed-dose combinations.